Quetiapine ('Seroquel'): A new "atypical" antipsychotic

Journal of Practical Psychiatry and Behavioral Health

Volumn 3, Issue 6, 1997, Pages 368-373

  Weiden, Peter I ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749101875     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Migler B, Warawa E, Malick J. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 1993;112:299-307.
2. Goldstein J, Arvanitis L. ICI 204,636 (Seroquel): A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and the highlights of Phase II clinical trials. CNS Drug Review 1995;1:50-73.
3. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. The time course and central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine ('Seroquel') in male patients with schizophrenia. Psychopharmacology. (in press).
4. Casey D. 'Seroquel' (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic. Exp Opinion Investigational Drugs 1996;5:939-57.
5. Goldstein J, Arvanitis L. 'Seroquel' (quetiapine) is not associated with dose-related extrapyramidal symptoms: Overview of clinical results. Schizophr Res 1997;24:198 (abstract).
6. Small J, Hirsch S, Arvanitis L, et al. Quetiapine in patients with schizophrenia: A high-and low-dose double blind comparison with placebo. Arch Gen Psychiatry 1997;54: 549-57.
7. Thyrum P, Fabre L, Wong Y, Ewing B, Yeh C. Multiple-dose pharmacokinetics of ICI 204,636 in schizophrenic men and women. Psychopharmacol Bull 1996;32:524A (abstract).
8. Thyrum P, Fabre L, Wong Y, Ewing B, Yeh C. Multiple-dose pharmacokinetics of ICI 204,636 in elderly patients with selected psychotic disorders. Psychopharmacol Bull 1996;32:524A (abstract).
9. Grimm S, Stam K, Bui K In vitro prediction of potential metabolic drug interactions for Seroquel. Schizophr Res 1997;24:198 (abstract).
10. Wong J, Ewing J, Thyrum P, Yeh C, Doane J, Marbury T. Kinetics of 'Seroquel' in hepatic and renal insufficiency. World Congress of Psychiatry. Madrid, Spain; 1996:300.
11. Wong J, Ewing J, Thyrum P, Yeh C, Potkin S. Effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics of quetiapine. NCDEU, Boca Raton, Florida; 1997.
12. Arvanitis L, Rak I. The long-term efficacy and safety of 'Seroquel' (quetiapine). Schizophr Res 1997;24:196 (abstract).
13. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
14. Arvanitis L, Rak I. Efficacy, safety, and tolerability of 'Seroquel' (quetiapine) in elderly subjects with psychotic disorders. Schizophr Res 1997;24:196 (abstract).
15. Chylack LTJ. Cataracts and inhaled corticosteroids (response). N Engl J Med 1997:337:46-8.
16. Smith D, Pantelis C, McGrath J, Tangas C, Copolov D. Ocular abnormalities in chronic schizophrenia: Clinical implications. Aust NZJ Psychiatry 1997;31:252-6.
17. Cumming MB, Mitchell P, Leeder SR. Use of inhaled corticosteriods and the risk of cataracts. N Engl J Med 1997;337:8-14.
18. Issac NE, Walker AM, Jick H, German M. Exposure to phenothiazine drugs and risk of cataract. Arch Ophthalomol 1991;109:256.
19. Weiden P, Aquila R, Standard J, Dalheim L. Switching antipsychotic medications. J Clin Psychiatry. 1997;58:63-72.